



OPEN ACCESS

EDITED AND REVIEWED BY

Takaji Matsutani,
Repertoire Genesis, Inc., Japan

*CORRESPONDENCE

Guangyu Ma
✉ mgy301@163.com
Ruimin Wang
✉ wrm@yeah.net
Shichun Lu
✉ lusc_301@163.com

†These authors have contributed equally to this work

RECEIVED 09 May 2023

ACCEPTED 12 May 2023

PUBLISHED 22 May 2023

CITATION

Wang G, Zhang W, Luan X, Wang Z, Liu J, Xu X, Zhang J, Xu B, Lu S, Wang R and Ma G (2023) Corrigendum: The role of 18F–FDG PET in predicting the pathological response and prognosis to unresectable HCC patients treated with lenvatinib and PD-1 inhibitors as a conversion therapy. *Front. Immunol.* 14:1219757. doi: 10.3389/fimmu.2023.1219757

COPYRIGHT

© 2023 Wang, Zhang, Luan, Wang, Liu, Xu, Zhang, Xu, Lu, Wang and Ma. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Corrigendum: The role of 18F–FDG PET in predicting the pathological response and prognosis to unresectable HCC patients treated with lenvatinib and PD-1 inhibitors as a conversion therapy

Guanyun Wang^{1,2†}, Wenwen Zhang^{3†}, Xiaohui Luan^{1,4}, Zhanbo Wang⁵, Jiabin Liu¹, Xiaodan Xu¹, Jinming Zhang¹, Baixuan Xu¹, Shichun Lu^{3*}, Ruimin Wang^{1*} and Guangyu Ma^{1*}¹Department of Nuclear Medicine, The First Medical Centre, Chinese People's Liberation Army (PLA) General Hospital, Beijing, China, ²Nuclear Medicine Department, Beijing Friendship Hospital, Capital Medical University, Beijing, China, ³Faculty of Hepato-Pancreato-Biliary Surgery, Chinese People's Liberation Army (PLA) General Hospital/Institute of Hepatobiliary Surgery of Chinese People's Liberation Army/Key Laboratory of Digital Hepetobiliary Surgery, People's Liberation Army, Beijing, China, ⁴Graduate School, Medical School of Chinese People's Liberation Army (PLA), Beijing, China, ⁵Department of Pathology, The First Medical Centre, Chinese People's Liberation Army (PLA) General Hospital, Beijing, China

KEYWORDS

unresectable hepatocellular carcinoma, conversion therapy, major pathological response, prognosis, ¹⁸F-FDG PET

A corrigendum on

The role of 18F–FDG PET in predicting the pathological response and prognosis to unresectable HCC patients treated with lenvatinib and PD-1 inhibitors as a conversion therapyby Wang G, Zhang W, Luan X, Wang Z, Liu J, Xu X, Zhang J, Xu B, Lu S, Wang R and Ma G (2023). *Front. Immunol.* 14:1151967. doi: 10.3389/fimmu.2023.1151967

In the published article, there was an error in the formula in the manuscript.

A correction has been made to **Materials and Methods**, Image analysis, Paragraph 2. This sentence previously stated:

“The percentages of post-treatment changes in metabolic parameters were calculated as follows:

$$\Delta\text{SUV}_{\text{max}}(\%) = \frac{\text{SUV}_{\text{max}} \text{ of pre-treatment} - \text{SUV}_{\text{max}} \text{ of post-treatment}}{\text{SUV}_{\text{max}} \text{ of pretreatment}} \times 100\%$$

$$\Delta\text{TLR}(\%) = \frac{\text{TLR of pre-treatment} - \text{TLR of post-treatment}}{\text{TLR of pre-treatment}} \times 100\%$$

$$\Delta\text{PLR}(\%) = \frac{\text{PLR of pre-treatment} - \text{PLR of post-treatment}}{\text{PLR of pre-treatment}} \times 100\%$$

The corrected sentence appears below:

“The percentages of post-treatment changes in metabolic parameters were calculated as follows:

$$\Delta\text{SUVmax}(\%) = \frac{\text{SUVmax of post-treatment} - \text{SUVmax of pre-treatment}}{\text{SUVmax of pre-treatment}} \times 100\%$$

$$\Delta\text{TLR}(\%) = \frac{\text{TLR of post-treatment} - \text{TLR of pre-treatment}}{\text{TLR of pre-treatment}} \times 100\%$$

$$\Delta\text{PLR}(\%) = \frac{\text{PLR of post-treatment} - \text{PLR of pre-treatment}}{\text{PLR of pre-treatment}} \times 100\%$$

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.